Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blinded, Adaptive Phase 2 Study to Evaluate the Safety and Efficacy of IV or IV/PO Omadacycline and IV/PO Levofloxacin in the Treatment of Adults With Acute Pyelonephritis

Trial Profile

A Randomized, Double-Blinded, Adaptive Phase 2 Study to Evaluate the Safety and Efficacy of IV or IV/PO Omadacycline and IV/PO Levofloxacin in the Treatment of Adults With Acute Pyelonephritis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omadacycline (Primary) ; Omadacycline (Primary) ; Levofloxacin; Levofloxacin
  • Indications Pyelonephritis
  • Focus Therapeutic Use
  • Sponsors Paratek Pharmaceuticals
  • Most Recent Events

    • 08 Nov 2019 Status changed from active, no longer recruiting to completed.
    • 31 Oct 2019 Status changed from recruiting to active, no longer recruiting, according to a Paratek Pharmaceuticals media release.
    • 31 Oct 2019 According to a Paratek Pharmaceuticals media release, additional analyses are ongoing and the company plans on presenting data from the study at a future medical conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top